DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DarioHealth excels in Q4 2022 with B2B growth and strategic partnerships

DarioHealth's Q4 2022 marked strong financial performance and operational efficiency gains.
Strategic focus on B2B model and multi-condition management driving revenue growth.
Challenges include managing increased expenses and maintaining high gross margin targets.
Opportunities lie in expanding client base, strategic integrations, and revenue diversification.

DarioHealth reports revenue growth and strategic partnerships driving future expansion

DarioHealth's Q1 2023 performance showed revenue growth, improved margins, and strategic focus on B2B.
Strong partnerships with Amwell and Sanofi position the company for multi-condition agreements and revenue growth.
Operational challenges in DTC margins and user comparison require attention for sustained growth.
Opportunities lie in hospitalization reduction, revenue growth from partnerships, and market expansion through Aetna launch.

DarioHealth reports steady Q2 performance, eyes growth through partnerships

DarioHealth's Q2 2023 performance showcased steady B2B2C ARR growth despite flat revenue, with improving gross margins and reduced operating losses, supported by a strong cash position.
The company's strengths lie in strategic partnerships, market fit, and operational efficiency, while facing challenges in revenue growth rates and optimizing expenses.
Opportunities ahead include revenue growth through partnerships and new product launches, leveraging AI for engagement and cost efficiencies, and sustaining a software-driven business model.

DarioHealth reports growth in Q3 2023, eyes revenue diversification

DarioHealth's Q3 2023 showed growth and improved financial metrics.
Strategic partnerships and revenue diversification are key strengths.
Challenges include predicting revenue recognition and cost management.
Opportunities lie in revenue growth and becoming cash flow positive.

DarioHealth reports robust Q4 results, eyes growth through strategic acquisitions

DarioHealth's strong Q4 performance and strategic acquisitions position the company for growth in 2024 and 2025, with a focus on profitability and revenue expansion.
While facing challenges in revenue scaling and cost reduction, the company's strengths in cash position, innovation, and leadership integration provide a solid foundation for success.
Opportunities lie in revenue growth from partnerships and acquisitions, integration synergies, and advancements in digital solutions, driving DarioHealth's path to market differentiation and financial success.

DarioHealth excels in Q1 2024, eyes profitability post Twill merger

DarioHealth's strong Q1 performance driven by B2B2C growth, poised for profitability post Twill merger. Focus on product integration and revenue expansion in key channels.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023 NEW YORK , Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025.   Dario has added four new employer contracts to the 2025 book of business, continuing the business momentum in the Business-to-Business-to-Consumer (B2B2C) channel and securing recurring revenue from these accounts starting in the first quarter of 2025.

Dario Signs Four New Employer Contracts Across Full Product Suite

DarioHealth Corp. (NASDAQ:DRIO ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Third Quarter 2024 Results Call. [Operator Instructions] This call is being recorded on November 7, 2024.

DarioHealth Corp. (DRIO) Q3 2024 Earnings Call Transcript

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.49 per share a year ago.

DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates

Demonstrated strong improvements in financial performance and business momentum. Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.

DarioHealth Reports Third Quarter 2024 Financial and Operating Results

The new platform services subscription contract with a top six U.S. pharma client marks a pivotal shift in Dario's pharma channel, transitioning the business model from milestone-based to recurring service subscription fees by expanding engagement with payors and pharmacy benefit managers (PBMs) NEW YORK , Nov. 4, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new collaboration with a pharma company that will utilize Dario Connect (formerly Twill Care) among their patient populations to further their direct-to-consumer efforts using Dario's refined engagement and navigation technologies. In an effort to strengthen and expand connections across patient populations that are candidates for a new drug to treat psoriasis, a top pharmaceutical company chose Dario to pilot a cutting-edge initiative aimed to help onboard patients that will engage with the drug via the platform.

Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement

The new contract marks the eighth health plan for Dario and will contribute to revenues starting immediately. NEW YORK , Oct. 30, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a regional health plan in the Medicaid space, which has launched with the full suite of cardiometabolic solutions.

Dario Signs New Regional Health Plan, Expanding Reach in Medicaid Population

Company to host conference call and webcast at 8:30am ET NEW YORK , Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens.     Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.

DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th

Integration of behavioral health and wellbeing solutions with navigation and engagement technology creates the most comprehensive solution in the market under the Dario brand NEW YORK , Oct. 17, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, today announces the full integration of Twill's advanced behavioral health and navigation capabilities into the Dario platform. The integration completes Dario's effort to create one of the most comprehensive and effective end-to-end digital health solutions in the market.

Dario Announces Complete Integration of Twill Capabilities Across Full Multi-Condition Platform

New offer gives Dario access to millions of AARP members, enabling engagement with people over 50 in health and well-being beginning in January 2025 NEW YORK , Oct. 15, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new AARP member benefit that provides members with proven digital behavioral health and well-being solutions from Twill by Dario. The new benefit is expected to launch in January of 2025 for AARP members.

Twill by Dario to Offer a Benefit for AARP Members

DarioHealth (DRIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About DarioHealth (DRIO) Rating Upgrade to Strong Buy

The new contract significantly expands Dario's footprint with more than a million eligible members beginning January 2025 NEW YORK , Oct. 1, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national Medicare Advantage health plan (the "Plan") to launch its behavioral health solution for the Plan members beginning in January 2025.     This new contract marks the beginning of a strategic relationship, starting with Dario's behavioral health solution, Twill by Dario, in 2025 and potentially expanding to additional Dario solutions in 2026 and beyond.

National Medicare Health Plan Partners with Twill by Dario to Promote Healthy Aging with New Digital Mental Health Benefits for Seniors

HealthEquity

The RealReal

TAL Education Group

Energous

Tap five stocks with increasing P/E ratios. These stocks include TAL Education Group (TAL), The RealReal (REAL), DarioHealth (DRIO), HealthEquity (HQY) and Energous (WATT).

Bet on 5 Top-Ranked Stocks With Rising P/E for Stellar Gains

The Dow Jones index closed higher by more than 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

DarioHealth And 2 Other Stocks Under $5 Executives Are Buying

The integration of Twill's condition-specific, expert-led peer groups will enhance the member experience and deepen engagement with Dario's proven cardiometabolic solution NEW YORK , Sept. 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the integration of condition-specific communities and peer groups with personalized navigation capabilities into its cardiometabolic solution to improve outcomes-based engagement, marking a significant milestone in the integration of the Dario-Twill product offering.

Dario Introduces Integration of Twill Behavioral Health Capabilities into Cardiometabolic Health Solution to Enhance Member Engagement and Outcomes

New Research Confirms the Benefit of Dario's Integrated, Data-Driven Approach to Health and Chronic Condition Management NEW YORK , Sept. 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the publication of a new study in the peer-reviewed journal Frontiers in Endocrinology.

Dario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes

DarioHealth Corp. (NASDAQ:DRIO ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Conference Call Participants Lucas Romanski - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Second Quarter 2024 Results Conference Call. At this time, all lines are in a listen-only mode.

DarioHealth Corp. (DRIO) Q2 2024 Earnings Call Transcript

DarioHealth Corp. (DRIO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.29 per share. This compares to loss of $0.58 per share a year ago.

DarioHealth Corp. (DRIO) Q2 Earnings Beat Estimates

Q2 revenue of $6.26 million reflects an increase of 8.6% over Q1 2024, and an increase of 1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues Q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for Q2 of 2023, representing a 105% increase Core B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024 Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring, and more stable revenue-based business model in our pharma channel, which is currently milestone based. Strong business momentum on cross selling of Twill offering to Dario clients with at least 10 initial clients Executed on Dario-Twill synergies that expect to reduce operating expenses by approximately 40% by Q1 2025 compared to Q1 2024, aiding in an expected reduction in operating losses of at least 70% by Q1 2025 Saw increased GLP-1 product adoption across new and existing clients seeking our metabolic solutions, with 9 clients implementing already and several more expected in 2024.

DarioHealth Reports Second Quarter 2024 Financial and Operating Results

Company to host conference call and webcast at 8:30am ET NEW YORK , July 30, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.

DarioHealth to Report Second Quarter 2024 Results on Thursday, August 8th

Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets NEW YORK , July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees beginning in the third quarter of 2024. The employer, a leader in environmental services, selected Dario's cardiometabolic suite to address multiple health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including integrated support for those employees taking a GLP-1 medication.

Dario Expands GLP-1 Solution Client Base with New Employer Contract

New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1 Additional research demonstrates 31% of Dario members with Type 2 diabetes achieve results reflecting diabetes remission NEW YORK , June 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies presented this past weekend at the 84th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando. The first study provides an analysis of member data for those tracking a GLP-1 medication in Dario's cardiometabolic solution.

Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1

Aeva Technologies Inc

Duos Technologies Group

While the innovation sphere constantly focuses on artificial intelligence these days, the top players in the field have gotten a lot of attention – maybe too much attention. Recently, we've seen the mighty Nvidia (NASDAQ: NVDA ) lose a step from its previously mercurial ways.

3 Small-Cap AI Stocks to Buy Now: June 2024

After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK , June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitability.

Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

DarioHealth Corp. (NASDAQ:DRIO ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Kat Parrella - IR Erez Raphael - CEO Rick Anderson - President Conference Call Participants Adam Chazan - TD Cowen Operator Good morning ladies and gentlemen and welcome to the DarioHealth First Quarter 2024 Results Conference Call. At this time, all lines are in a listen-only mode.

DarioHealth Corp. (DRIO) Q1 2024 Earnings Call Transcript

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.45 per share a year ago.

News for DarioHealth Stock (DRIO)